Work Here?
Overview
Virbac provides care, hygiene and nutrition products to prevent, diagnose and treat animal diseases. Its offerings are designed for veterinarians, farmers and pet owners worldwide, delivering complete animal-health solutions through a global network of production sites, sales subsidiaries and R&D centers across five continents. The product approach combines prevention, diagnosis and treatment in veterinary medicine, not limited to a single animal type. What sets Virbac apart is its scale and mix: a broad international footprint (production sites in 12 countries, sales subsidiaries in 36) and a substantial share of sales outside Europe, with a clear focus on both companion animals (roughly 61% of 2025 sales) and farm animals (39%). The company aims to advance animal health by empowering those who care for animals daily, helping people and animals live better together.
About Virbac
Industries
Industrial & Manufacturing
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Carros, France
Founded
1968
Get referred to Virbac
See people who can refer or advise you
Simplify's Take
What believers are saying
- Virbac India reached Rs 1,650 crore turnover and over 1,600 employees by September 2026.
- FDA lifted the 2015 St. Louis Warning Letter, clearing a long-standing U.S. manufacturing drag.
- Morningstar Sustainalytics named Virbac a 2026 Industry ESG Leader, supporting premium employer branding.
What critics are saying
- Virbac booked €5.6 million H1 2026 one-offs from product discontinuation and damages.
- Sébastien Huron's departure in 2024 and 2026 governance reorganization signal leadership instability.
- Patent, competition, and tax disputes remain active; an adverse case can hit cash and launches.
What makes Virbac unique
- Virbac's H1 2026 revenue rose 7.4% at CERS, with 18.8% adjusted EBIT margin.
- Virbac secured exclusive MACSO swine-monitoring rights across Europe, Latin America, and Asia in March 2026.
- Virbac launched Porus-One and Lystralin distribution deals, targeting 2027 specialty-acquisition launches.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Disability Insurance
Meal Benefits
Relocation Assistance
Employee Discounts
Profit Sharing
Stock Price
Company News
Sangri buzz. NewsVoir. Virbac Animal Health India marks two decades of operations with significant business growth, strategic investments, an expanding regional footprint and recognition as a Great Place to Work(R). Sep 21, 2026 13:56 PM Mumbai, India Virbac Animal Health India is celebrating 20 years of advancing animal health by responding to the evolving needs of veterinarians, farmers and pet owners through science, innovation and comprehensive healthcare solutions. Over two decades, the company has continuously expanded its portfolio, strengthened its scientific and manufacturing capabilities and introduced new approaches to prevention, diagnosis, treatment, hygiene and nutrition across India's diverse animal health needs. Natesan Thanthoni, Area Director - India, Middle East & Africa (IMEA), Virbac Animal Health Virbac India's journey has also delivered significant business growth. From a Rs 100 crore organisation with around 200 employees, the company has grown to a consolidated turnover of Rs 1,650 crore and a workforce of more than 1,600 employees. Over the past two decades, Virbac India has also evolved into one of the highest contributing subsidiaries within the global Virbac Group, reflecting its strong business performance, manufacturing excellence and strategic importance in the company's worldwide operations. Over the past two decades, Virbac India has built a strong presence across the cattle, poultry, sheep, aquaculture and companion animal healthcare sectors by consistently investing in scientific innovation, manufacturing excellence and customer-centric solutions. Today, the company serves veterinarians, farmers and pet parents across the country through a comprehensive portfolio of therapeutics, vaccines, biologicals, disinfectants, nutritional supplements and preventive healthcare solutions. The company's growth has been shaped by a combination of sustained organic expansion and strategic acquisitions that have strengthened its capabilities across key segments. The acquisition of the Agrivet Farmcare division of GSK started Virbac's journey in India and expanded its presence across animal healthcare segments. The subsequent acquisition of Globion and integration into the Virbac ecosystem as Virbac Biologicals further enhanced the company's capabilities in poultry vaccines, biologicals and preventive healthcare. These strategic milestones have strengthened the company's manufacturing capabilities, research expertise and ability to deliver science-led solutions tailored to India's evolving animal healthcare needs. The company's growth has been accompanied by a strong focus on its people and workplace culture. Virbac India has been recognised as a Great Place to Work(R), reflecting its continued efforts to build an inclusive, collaborative and people-centric workplace. This recognition reinforces the importance the organisation places on employee experience, trust, professional development and a culture that enables its people to contribute to the company's long-term growth. Commenting on the milestone, Natesan Thanthoni, Area Director - India, Middle East & Africa (IMEA), said, "Completing 20 years in India is a proud milestone that reflects the trust of our customers, the dedication of our employees and the strength of our long-term partnerships with the veterinary community. From a Rs 100 crore organisation to a Rs 1,635 crore company, our journey has been driven by a singular focus on advancing animal health through science and innovation. Every milestone, whether expanding our manufacturing capabilities, strengthening our portfolio through strategic acquisitions or investing in biologicals and preventive healthcare, has been guided by creating long-term value. As we enter the next phase of growth, we remain committed to delivering science-led solutions that improve animal health while supporting veterinarians, farmers and pet parents across India and the wider IMEA region." The evolution of India's animal healthcare sector over the past two decades has seen growing demand for preventive healthcare, biologicals, nutrition and advanced therapeutics. Virbac India has continuously adapted its portfolio to address these changing needs by combining global scientific expertise with local market insights and manufacturing capabilities. This commitment reflects Virbac's broader approach of constantly exploring new ways to prevent, diagnose and treat animal pathologies while developing care, hygiene and nutrition products that provide complete solutions for veterinarians, farmers and pet owners. Beyond business growth, the company has remained focused on building a collaborative and innovation-driven organisational culture. Its workforce has expanded from approximately 200 employees at the time of inception to more than 1,600 professionals today, reflecting sustained investments in talent development, operational excellence and customer engagement. The Great Place to Work(R) recognition further reflects the company's focus on creating an environment where employees can grow, collaborate and contribute meaningfully to Virbac India's continued progress. As Virbac India begins its next chapter, the company will continue to strengthen its leadership in preventive healthcare, biologicals, nutrition and advanced therapeutics while investing in manufacturing, research and customer partnerships to address the evolving needs of India's animal health sector and contribute to better health and wellbeing for animals across the country and the wider IMEA region.
Virbac India celebrates 20 years of advancing Animal Health through science, innovation and sustainable growth. ANI | Updated: Sep 21, 2026 14:50 IST NewsVoirMumbai (Maharashtra) [India], September 21: Virbac Animal Health India is celebrating 20 years of advancing animal health by responding to the evolving needs of veterinarians, farmers and pet owners through science, innovation and comprehensive healthcare solutions. Over two decades, the company has continuously expanded its portfolio, strengthened its scientific and manufacturing capabilities and introduced new approaches to prevention, diagnosis, treatment, hygiene and nutrition across India's diverse animal health needs.Virbac India's journey has also delivered significant business growth. From a Rs 100 crore organisation with around 200 employees, the company has grown to a consolidated turnover of Rs 1,650 crore and a workforce of more than 1,600 employees. Over the past two decades, Virbac India has also evolved into one of the highest contributing subsidiaries within the global Virbac Group, reflecting its strong business performance, manufacturing excellence and strategic importance in the company's worldwide operations.Over the past two decades, Virbac India has built a strong presence across the cattle, poultry, sheep, aquaculture and companion animal healthcare sectors by consistently investing in scientific innovation, manufacturing excellence and customer-centric solutions. Today, the company serves veterinarians, farmers and pet parents across the country through a comprehensive portfolio of therapeutics, vaccines, biologicals, disinfectants, nutritional supplements and preventive healthcare solutions.The company's growth has been shaped by a combination of sustained organic expansion and strategic acquisitions that have strengthened its capabilities across key segments. The acquisition of the Agrivet Farmcare division of GSK started Virbac's journey in India and expanded its presence across animal healthcare segments. The subsequent acquisition of Globion and integration into the Virbac ecosystem as Virbac Biologicals further enhanced the company's capabilities in poultry vaccines, biologicals and preventive healthcare. These strategic milestones have strengthened the company's manufacturing capabilities, research expertise and ability to deliver science-led solutions tailored to India's evolving animal healthcare needs. The company's growth has been accompanied by a strong focus on its people and workplace culture. Virbac India has been recognised as a Great Place to Work(R), reflecting its continued efforts to build an inclusive, collaborative and people-centric workplace. This recognition reinforces the importance the organisation places on employee experience, trust, professional development and a culture that enables its people to contribute to the company's long-term growth.Commenting on the milestone, Natesan Thanthoni, Area Director - India, Middle East & Africa (IMEA), said, "Completing 20 years in India is a proud milestone that reflects the trust of our customers, the dedication of our employees and the strength of our long-term partnerships with the veterinary community. From a Rs 100 crore organisation to a Rs 1,635 crore company, our journey has been driven by a singular focus on advancing animal health through science and innovation. Every milestone, whether expanding our manufacturing capabilities, strengthening our portfolio through strategic acquisitions or investing in biologicals and preventive healthcare, has been guided by creating long-term value. As we enter the next phase of growth, we remain committed to delivering science-led solutions that improve animal health while supporting veterinarians, farmers and pet parents across India and the wider IMEA region."The evolution of India's animal healthcare sector over the past two decades has seen growing demand for preventive healthcare, biologicals, nutrition and advanced therapeutics. Virbac India has continuously adapted its portfolio to address these changing needs by combining global scientific expertise with local market insights and manufacturing capabilities. This commitment reflects Virbac's broader approach of constantly exploring new ways to prevent, diagnose and treat animal pathologies while developing care, hygiene and nutrition products that provide complete solutions for veterinarians, farmers and pet owners.Beyond business growth, the company has remained focused on building a collaborative and innovation-driven organisational culture. Its workforce has expanded from approximately 200 employees at the time of inception to more than 1,600 professionals today, reflecting sustained investments in talent development, operational excellence and customer engagement. The Great Place to Work(R) recognition further reflects the company's focus on creating an environment where employees can grow, collaborate and contribute meaningfully to Virbac India's continued progress.As Virbac India begins its next chapter, the company will continue to strengthen its leadership in preventive healthcare, biologicals, nutrition and advanced therapeutics while investing in manufacturing, research and customer partnerships to address the evolving needs of India's animal health sector and contribute to better health and wellbeing for animals across the country and the wider IMEA region.(ADVERTORIAL DISCLAIMER: The above press release has been provided by NewsVoir. ANI will not be responsible in any way for the content of the same)
Virbac partners with MapMyWalk on dog walking challenge tied to mobility supplements. The Keep Moving Activation ties in-app walking milestones to discount codes for Virbac's URSOLYX and MOVOFLEX chews. Virbac has partnered with MapMyWalk, a GPS-based walking and fitness app, on a consumer campaign encouraging dog owners to log walks with their pets. The Keep Moving Activation, announced August 28, links in-app walking challenges to Virbac's canine joint and muscle-health supplement line. The Dog Days of Summer Challenge runs through September 27, 2026: participants log 10 walking, running, or hiking activities with their dogs to hit 5 milestones. Those who complete 4 receive a discount code for URSOLYX Soft Chews for Dogs.[1] A second challenge, Fall Flex, runs October 13 through November 12 and offers a discount on MOVOFLEX Advanced Soft Chews to those completing 4 of its activities. Participation is free through the MapMyWalk app. According to Virbac, more than half of dogs age 7 and older experience muscle atrophy and joint or muscle changes affecting quality of life. "Make every walk count" "Movement is a powerful indicator of a pet's health, and it's something dogs and their owners share every day," said Mark Champ, vice president of marketing for Virbac US, in an announcement.[1] "By teaming up with MapMyWalk, we're encouraging pet parents to make every walk count, for their dog's mobility and their own." Both challenges are open nationwide to MapMyWalk users at no additional cost beyond app access. * Virbac Calls On Pet Owners to Keep Moving in New MapMyWalk Activation. Media alert. Virbac. August 28, 2026.
Animal health companies report resilient Q2 and H1 results despite market pressures. Elanco, Virbac, Boehringer Ingelheim, ADM and Pet Service Holding post higher revenue and earnings. New product launches, dermatology, pet nutrition and operational efficiencies supported growth across several of the industry's largest animal health companies. GlobalPETS analyses the latest earnings results from five key players. Elanco. Indiana-based animal health company Elanco reported a 12% year-over-year (YoY) increase in pet health revenue for the second quarter of 2026, reaching $718 million (€618M). On an organic constant currency basis, segment revenue grew 11%, driven by a 9% increase in volume and a 2% price expansion. "We saw strong contributions from both price and volume, as consumer demand for our basket of innovation drove market share gains and stabilized our base business," says President and CEO Jeff Simmons. Its newest dermatology product for the treatment of pruritus associated with allergic dermatitis was the company's largest contributor to global growth. The company said the product expanded into approximately 18,000 U.S. clinics and reached up to a 40% market share in key European markets. Across the group, Elanco generated revenue of $1.368 billion (€1.18B) in Q2 2026, up 10% year over year on a reported basis and 8% on an organic constant currency basis. The company raised its full-year 2026 revenue guidance to between $5.09 billion and $5.14 billion (€4.38B-€4.42B) and increased its annual innovation revenue target to $1.25 billion (€1.08B). ADM. The Animal Nutrition segment of US food processing company ADM generated an operating profit of $33 million (€28M) for the second quarter of 2026, representing a 50% increase from the $22 million (€19M) reported in the same period of 2025. The growth was driven by strategic initiatives and improved operational efficiency across the business. The company also said it benefited from strategic portfolio actions implemented during 2025. Globally, ADM reported net earnings of $908 million (€782M) in Q2 2026 and raised its full-year 2026 adjusted EPS guidance to between $5.15 (€4.44) and $5.60 (€4.83) per share, up from the previous range of $4.15 (€3.58) to $4.70 (€4.05) per share. Virbac. French animal health company Virbac reported 10% year-over-year (YoY) growth in its companion animal segment during the first half (H1) of 2026, helping the company generate revenue of €768 million ($879M). Revenue increased 7.4% at constant exchange rates and scope (CERS) and 4% at actual exchange rates, which the company said were impacted by currency headwinds. Europe, Virbac's second-largest market, accounted for 40% of sales and generated €314 million ($359M) in revenue, up 6.5%, supported by the companion animal business. "Growth was mainly driven by the companion animal segment (7.2% at CER), primarily fueled by our pet food and endocrinology ranges following the Thyronorm acquisition," the company says. The pet portfolio also recorded double-digit growth in the international segment, which includes IMEA (India, Middle East and Africa) and Latin America. Performance was driven by strong demand for pet food, dental care and vaccine products. During the first half of the year, the international segment generated €351 million ($401M) in revenue, accounting for 46% of total sales. North America accounted for 13.4% of total revenue, with sales of €103 million ($118M). It recorded the strongest regional growth, increasing 10.1% at constant exchange rates (CER). In Q2, the company's "supercharge categories" - mobility, dental care and ear care - performed particularly well. This helped drive 9.1% growth in the companion animal segment, offsetting lower sales in the farm animal business, which were impacted by supply challenges. Although the company maintained its full-year guidance of 5.5% to 7.5% revenue growth at CERS, Virbac said its "strong first-half momentum positions us to target the upper end." Pet Service Holding. Dutch pet care firm Pet Service Holding (PSH) registered an 8% increase in revenue during the first half of 2026, which totaled €7.4 million ($8.5M). "The Group's optimized product range, which includes a significant proportion of over-the-counter (OTC) veterinary medicines and pet accessories. This offset the impact of the revised regulatory framework applicable to prescription veterinary medicines," the company said in a statement. During the period, PSH decided to phase out sales to veterinary purchasing groups and practice networks that did not meet its minimum profitability requirements. "While this decision limited short-term revenue growth in this business segment, it strengthened its gross margin by prioritizing sustainable and profitable sales over volume alone." Positive contributions also came from Petlux, a manufacturer and distributor of luxury pet products acquired in 2025; a fully operational production factory in China; and the opening of its first discount store concept Budget Pets in Bussum, near Amsterdam. For the second half of 2026, results will reflect the acquisition of the supplier of cat furniture and scratching posts RHR Concepts, completed during H1. "In light of these developments, the company is confident in its ability to achieve sales of approximately €17 to €18 million ($19.6M-$20.7M) in 2026, along with improved operating margins," it added. Growth is accelerating from fiscal year (FY) 2025, when sales summed €13.6 million ($16M) at a 7.7% year-over-year (YoY) rise. Boehringer Ingelheim. German pharmaceutical company Boehringer Ingelheim reported a 16.2% YoY increase in group net sales for the first half of 2026 to €15.8 billion ($18.3B). Its Animal Health division, which includes products for pets, contributed €2.6 billion ($3B) in net sales, with the remainder generated by its Human Pharma business. According to the company, the marginal growth of 0.4% in the Animal Health division reflected a slow expansion in the market amid increased consumer price sensitivity and fewer veterinary visits in several countries. For the remainder of the fiscal year, Boehringer Ingelheim plans to continue executing its 2026 product launches and market expansions. These include an AI-based tool that helps detect heart murmurs in dogs, which is currently available in the US, the UK and Germany. The company also continues to support responses to emerging animal disease outbreaks, including outbreaks of New World screwworm in the US, after receiving emergency use authorizations (EUAs) from the US Food and Drug Administration earlier this year. "Looking ahead, we need to direct our long-term investments to where they are closest to our growth markets and where they can create the best possible impact for patients," says Frank Hübler, Member of the Board of Managing Directors responsible for Finance. Free articles read this month
Virbac participated in the 2026 Clinical Nutrition and Gastroenterology Forum with VETERINARY HPM(R). Posted on 14/07/2026 Virbac Peru participated in the 2026 Clinical Nutrition and Gastroenterology Forum, a scientific update event that brought together veterinarians specializing in companion animals to share knowledge and learn about the latest developments in veterinary clinical nutrition and gastroenterology. During the event, Virbac showcased its portfolio of animal health solutions, highlighting VETERINARY HPM(R)- its veterinary nutrition line developed around the concept of high animal-based protein and low carbohydrate content. This line is formulated to meet the natural nutritional needs of dogs and cats and to aid in the nutritional management of various clinical conditions. Attendees also learned about other solutions in Virbac's portfolio for comprehensive pet care, including products for dermatological and ear health, internal and external parasite control, and various therapeutic options that support the daily work of veterinarians. Virbac's participation in this forum reaffirms its commitment to continuing education, innovation, and the development of science-backed solutions. By fostering knowledge exchange and promoting evidence-based veterinary medicine, the company aims to improve the quality of life for dogs and cats. Agrovetmarket thank all the veterinarians who visited its booth and shared in this learning experience. Agrovetmarket will continue to participate in the country's leading scientific events to drive professional development and bring innovative animal health solutions closer to the veterinary community.
Virbac is Hiring for 96 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Virbac
Industries
Industrial & Manufacturing
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Carros, France
Founded
1968
Virbac is Hiring for 96 Jobs on Simplify!
Find jobs on Simplify and start your career today